Brokerages Set GH Research PLC (NASDAQ:GHRS) Target Price at $34.11

GH Research PLC (NASDAQ:GHRS) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $34.1111.

GHRS has been the topic of a number of research reports. Royal Bank Of Canada upped their price target on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. TD Cowen reiterated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Canaccord Genuity Group increased their target price on GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Wolfe Research set a $39.00 price target on shares of GH Research in a research note on Tuesday, January 6th.

Institutional Investors Weigh In On GH Research

Hedge funds have recently added to or reduced their stakes in the business. Stempoint Capital LP purchased a new stake in shares of GH Research during the second quarter worth $1,229,000. AdvisorShares Investments LLC grew its stake in GH Research by 15.0% during the 2nd quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company’s stock worth $466,000 after purchasing an additional 5,000 shares in the last quarter. Virtus Investment Advisers LLC acquired a new position in GH Research during the 2nd quarter worth $89,000. HighVista Strategies LLC purchased a new stake in GH Research during the 2nd quarter worth about $637,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research in the 4th quarter valued at about $38,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Price Performance

Shares of GHRS stock opened at $15.66 on Monday. GH Research has a 1-year low of $7.98 and a 1-year high of $20.50. The firm has a market cap of $814.79 million, a PE ratio of -21.16 and a beta of 0.99. The company has a 50-day moving average of $14.65 and a two-hundred day moving average of $14.01.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23). Sell-side analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.